This month the S&P 500 has fallen 4%. Breaking a streak of seven consecutive months of positive returns. Some of the names I like here include for who seeking for stocks to buy.
1. Cardiff Oncology, Inc. (NASDAQ:CRDF):
It’s really stocks to buy symbol. Equities analysts expect Cardiff Oncology, Inc. (NASDAQ:CRDF) to post sales of $60,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Cardiff Oncologys earnings.
The lowest sales estimate is $50,000.00 and the highest is $70,000.00. An insider buy and positive data may have boosted optimism.
Cardiff Oncology (NASDAQ: CRDF) , a clinical-stage biotech company specializing in new cancer treatments, saw its share price rise as high as $7.18 on Monday. It closed the day at $6.74, up about 7% from its previous close.
https://StockAndMore.com/ Price Target: 26.10 USD per share.
2. Sonnet BioTherapeutics, Inc. Holdings Inc. (NASDAQ:SONN):
Company announced the successful completion of the discovery phase for its next preclinical pipeline candidate, SON-1410.
The candidate represents Sonnet BioTherapeutics’ second bispecific compound integrating Interleukin 12 with the company’s Fully Human Albumin Binding platform. The target indications for SON-1410 will be melanoma and renal cancers.
https://StockAndMore.com/ Price Target: 8.10 USD per share.
3. Inovio Pharmaceuticals Inc (NASDAQ: INO) Is Stocks To Buy:
Final stocks to buy is INO. INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico News follows recent regulatory.
https://StockAndMore.com/ Price Target: 20.14 USD per share.
Thanks for reading.
Please check our Premium Area for more real-time updates.
Basic information about companies for who want to read more:
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer.
Lead drug candidate is onvansertib.
a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) has completed a Phase I clinical trial in advanced solid tumors and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin.
Onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers.
The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020.
Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action.
The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer.
Also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy.
It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system’s tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants.
The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).
Its partners and collaborators include
Beijing Advaccine Biotechnology Co., Ltd.,
The Bill & Melinda Gates Foundation,
Coalition for Epidemic Preparedness Innovations (CEPI),
Defense Advanced Research Projects Agency (DARPA),
HIV Vaccines Trial Network,
International Vaccine Institute,
Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC),
National Institutes of Health,
and Infectious Diseases,
National Institute of Allergy
the Parker Institute for Cancer Immunotherapy,
Plumbline Life Sciences,
National Cancer Institute,
Regeneron, Thermo Fisher Scientific,
University of Pennsylvania,
Walter Reed Army Institute of Research,
and The Wistar Institute.
The company also has an agreement with Richter-Helm BioLogics GmbH & Co KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is h eadquartered in Plymouth Meeting, Pennsylvania.